TLDR:
- Terumo Ventures will invest US$ 75 million over the next five years.
- New CVC increases agility in venture investments, enhancing technology acquisition.
Terumo Corporation has established “Terumo Ventures,” a Corporate Venture Capital (CVC) organization within Terumo Americas Holding, Inc. This new department aims to lead the Group’s venture investments by investing in early-stage companies primarily in the fields of cardiovascular disease treatment, chronic disease treatment, and digital technologies. Operating in global innovation hubs like Massachusetts and California, Terumo Ventures will invest US$ 75 million over the next five years. This investment will enhance Terumo’s access to innovative technologies and business ideas from start-ups while promoting open innovation and synergies with internal R&D efforts.
Since 2013, Terumo has been building relationships with medtech start-ups through investments in venture capital funds in the US and China. With the establishment of the CVC, the company aims to increase its agility in identifying, evaluating, and executing venture investments, accelerate the acquisition of cutting-edge technologies, and develop a robust M&A target pipeline for future growth. This initiative is aligned with Terumo’s 5-Year Growth Strategy ‘GS26’ and its long-term vision of ‘From Devices to Solutions.’
To strengthen its innovation capabilities, Terumo introduced a new director position in April 2024. This new role will centrally manage innovation-related functions across the company, including R&D, intellectual property, clinical development, digital transformation, and venture investment, fostering cross-functional collaboration. Moving forward, Terumo will continue to enhance its ability to create innovation through a combination of internal development and external partnerships to deliver innovative and comprehensive solutions to various medical challenges and unmet needs.
